Presentations in this symposium addressed effects and modes of action of endocannabinoids in various tissues in relation to metabolic disorders. Endocannabinoids are produced and exert their effect in various brain sites, including the mesolimbic reward circuitry and the hypothalamus. Both of these regions have direct ties to energy metabolism regulation, particularly food intake and energy expenditure. These data clearly suggest that the observed beneficial effects of CB1 (cannabinoid receptor 1) receptor antagonists on obesity may be related to the central endocannabinoid system. On the other hand, data presented on cannabinoid action in the liver and white adipose tissues clearly indicate that CB1-mediated events in affecting metabolic phenotype may occur in peripheral tissues as well. This together with the reported results from human trials on CB1 antagonists showing that the initial anorectic effect of rimonabant is diminished after the first weeks while longer lasting weight loss is achieved do indicate that peripheral action of cannabinoids are very important in body weight regulation. Should this hold true in the long run, antagonizing CB1 receptors with compound not crossing the blood-brain barrier could revolutionize pharmaceutical approaches to obesity by offering a tool that short cuts the central nervous system. International Journal of Obesity (2006) 30, S30-S32. doi:10.1038/sj.ijo.0803275
Western societies are endangered by increased energy intake and decreased energy expenditure. This leads to obesity, diabetes and other metabolic disorders that not only undermine classical endocrine mechanisms but also affect the development of other life-threatening illnesses, such as cancer and premature death. Although it is clear that in the majority of cases positive energy balance could be corrected with lifestyle changes and diet alterations, the fact that the obesity epidemic is steadily expanding suggest that a pharmacological approach would better suit Western populations. In light of this, it is not surprising that in the past century increasing attention has been paid to central and peripheral regulatory components of metabolism to develop treatment of eating disorders and obesity. The recent exciting results regarding antagonizing the endogenous cannabinoid system raised the potential for a successful strategy to treat metabolic disorders. The effects of cannabinoids, and their antagonists, on other brain sites, including the reward circuitry raise both the potential of intriguing new approaches to combat addictive disorders and more general issues such as the overall impact of anticannabinoids on human behavior and quality of life.
It is now well established that the hypothalamus plays a critical role in the regulation of energy balance. This was first suspected after descriptions of obesity in patients with hypothalamic tumors over a hundred years ago, 1 but at the time, it was thought that the pituitary gland regulated most endocrine functions and that alterations of the pituitary lead to metabolic disorders. 1 Confirmation of the hypothalamus as important for regulation of food intake and energy balance was obtained from animal studies using brain lesions of hypothalamic structures. [2] [3] [4] In essence, evidence obtained from both the clinical descriptions in tumor patients and from the lesion work showed that gross damage to mediobasal hypothalamic areas, in particular the ventromedial hypothalamic nucleus (VMH), was clearly associated with increased food intake, morbid obesity and insulin resistance, whereas damage to more lateral hypothalamic structures was associated with anorexia and adipsia. 5 In turn, electrical stimulation of the VMH resulted in decreased feeding, whereas stimulation of the lateral hypothalamic region increased appetite. [6] [7] [8] As a whole, these data suggested that the mediobasal hypothalamus was a satiety center, and that the lateral hypothalamus was an orexigenic center.
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The laboratory of Dr Uberto Pagotto has generated elegant data to suggest that the endogenous cannabinoid system potentially could affect energy metabolism through signaling in key hypothalamic areas. 11, 12 They detected CB1
(cannabinoid receptor 1) cannabinoid receptors in the mediobasal hypothalamus, paraventricular nucleus and in lateral hypothalamus where they colocalized them with neuronal subpopulations expressing either cocaine amphetamine transcript-expressing cells (arcuate nucleus), corticotrophin-releasing hormone (CRH)-producing neurons (PVN) and hypocretin/orexin and melanin-concentrating hormone (MCH) of the lateral hypothalamus. Hypocretin, MCH and CRH promote feeding, whereas CART is an anorexigenic neuropeptide. It is important to recognize, however, that CB1 expression in the hypothalamus in general, and the lateral hypothalamus in particular, is very minimal compared to CB1 expression in other brain areas, such as the hippocampus or the ventral striatum. 13 This latter region, the nucleus accumbens in particular, may play an important role in the mediation of the effects of cannabinoids on reward aspects of feeding: this area is a key component of the reward circuitry and cannabinoids have long been recognized as substances having a robust impact on reward In the hypothalamus, endocannabinoids (EC) and endogenous opioids affect the release of the above-mentioned neuromodulators. In the same manner, extrahypothalamic circuits present in reward-related brain structures, such as the ventral tegmental area (VTA), the prefrontal cortex (PFC) and the nucleus accumbens (NAcc), are affected by the actions of endocannabinoids. DA, dopamine; GABA, g-aminobutyric acid; Glut, glutamate. Question marks indicate putative presence of neurotransmitters GABA or glutamate content. In parallel, with actions in the central nervous system, cannabinoids appear to exert their effects on metabolism regulation by directly altering peripheral tissue function, most notably the liver and the white adipose tissue (WAT). Whether these peripheral effect occur independent of alterations in the central nervous system will need to be determined. If that were the case, it will open up novel possibilities for medical approaches of metabolic disorders shortcutting the brain.
pathways and associated food-seeking behavior. 13 Interestingly, a very recent paper on the role of the lateral hypothalamus in drug-seeking reinforcement was revealed with particular emphasis on the lateral hypothalamic hypocretin/orexin neurons. 14 Thus, the observations of the Pagotto's lab on CB1 expression in orexin neurons may tie to the regulation of feeding via mediation of the midbrain reward circuitry (Figure 1 ). Being aware of the retrograde signaling of endocannabinoids and suppression of release of neuromodulators from axon terminals upon CB1 activation, it will be an important task to determine how hypothalamic CB1 can alter circuitry function and how this relates to, or not for that matter, the robust effect of cannabinoids on feeding. Intriguingly, Pagotto and his colleagues also found, however, that while CBÀ/À animals are leaner because their calorie intake is lower in young age, in older animals, increased peripheral expenditure appears to dominate the relative negative energy balance of these animals compared to that of their wild-type littermates. 11 To this end, the observation of CB1 in adipocytes and that CB1 activation underlies lipogenesis provides an alternative and/or complementary mechanism for the unidirectional effect of cannabinoids on energy balance. That peripheral effects of cannabinoids may be critical on metabolism regulation could be derived from the presentation of Dr George Kunos as well. His laboratory analyzed the potential role of endocannabinoids in the regulation of hepatic lipogenesis. 15 They observed that activation of CB1 in mice elevated the hepatic gene expression of the lipogenic transcription factor SREBP-1c and its targets acetyl-CoA carboxylase-1 and fatty acid synthase (FAS). Promoting CB1 signaling also increased de novo fatty acid synthesis in the liver or in isolated hepatocytes, which expressed CB1. Although previous studies failed to detect CB1 in the liver, Kunos provided compelling evidence for its expression and a plausible explanation why it was missed earlier. They also found that high-fat diet increased hepatic levels of the endocannabinoid anandamide (arachidonoyl ethanolamide), CB1 receptor expression and basal fatty acid synthesis. Blockade of CB1 receptors reversed elevation in fatty acid levels. Thus, they suggested that endocannabinoids, anandamide in particular, acting on hepatic CB1 receptors contributes to diet-induced obesity and that the FAS pathway may be a common molecular target for central appetitive and peripheral metabolic regulation. 15 Presentations by Drs Despres and Le Fur were focusing on data gathered from clinical trials of the CB1 antagonist, rimonabant. The emerging data from human trials recapitulates, at least to some degree, findings on mice to the degree that there appears to be an initial phase during which food intake is diminished, but this is followed by maintenance of lower body weight for a longer period despite the fact that food intake returns to control values. The human as well as the rodent data, therefore, clearly argues for a dual mode of action of cannabinoids on energy metabolism: an early rapid but transient effect in the brain to suppress appetite and a concomitant or latent but prolonged effect on peripheral tissue metabolism. If it was the case that the overall longterm effects of CB1 antagonists on energy metabolism are primarily owing to a peripheral mode of action regardless of brain effects, selective targeting of peripheral CB1 receptors would provide a ideal therapeutic approach for metabolic disorders. Whether that is a feasible avenue, and thus brain side effects could be entirely prevented, is an intriguing question that needs to be addressed.
